CytoReason Raises $80M to Expand Computational Disease Models and Establish Office in Cambridge, MA

CytoReason Raises $80M in Funding

CytoReason raises $80M for Computational Disease Models

CytoReason (Linkedin), a leading biotech research company based in Israel, has secured an impressive $80 million in funding. This investment, led by OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific, will fuel CytoReason's expansion plans, including the application of their computational disease models and the establishment of an office in Cambridge, MA.

Funding Amount: $80 million

Industry: Biotechnology Research

Employee Count: 51-200

CEO: David H. (CEO Linkedin)

What CytoReason needs to buy: Pharmaceutical and biotech companies, research teams, and data organizations are ideal partners for CytoReason. These companies can support CytoReason in expanding their disease models, acquiring and analyzing data, establishing their office in Cambridge, MA, and driving market expansion through strategic partnerships and customer acquisition efforts.

CytoReason Raises $80M to Expand Computational Disease Models and Establish Office in Cambridge, MA

CytoReason raises $80M for Computational Disease Models

Read more

Supio Raises $25M in Series A Funding for AI Platform and Operational Expansion

Katara Raises $2.2M in Funding for Expansion

"Planera Raises $13.5M in Funding to Expand Construction Scheduling Platform"

pgEdge Raises $10M for Expansion and Innovation in Distributed PostgreSQL Market